Indication

in combination with nivolumab for the first-line treatment of advanced renal cell carcinoma in adults

Medicine details

Medicine name:
cabozantinib (Cabometyx)
SMC ID:
SMC2386
Pharmaceutical company
Ipsen Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Abbreviated
Publication due date:
11 October 2021